Q+A: Connor Frey, MD, on GLP-1 RAs and menstrual adverse event signals
Connor Frey, MD, explains why semaglutide and tirzepatide, but not liraglutide, generated menstrual adverse event signals in a FAERS pharmacovigilance analysis.
A disproportionality analysis of FDA Adverse Event Reporting System (FAERS) data, published in Obstetrics & Gynecology, found that semaglutide generated the broadest and strongest signal profile for menstrual adverse events among GLP-1 receptor agonists (GLP-1 RAs), with tirzepatide producing more limited signals and liraglutide producing none. The analysis, conducted by Connor Frey, MD, and Mahyar Etminan, PharmD, MSc, of the University of British Columbia, restricted FAERS reports to female patients aged 12 to 55 years from database inception through March 2026, yielding 4024 liraglutide reports, 27,469 tirzepatide reports, and 6060 semaglutide reports.1,2